|
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
|
US4179337A
(en)
|
1973-07-20 |
1979-12-18 |
Davis Frank F |
Non-immunogenic polypeptides
|
|
US4263428A
(en)
|
1978-03-24 |
1981-04-21 |
The Regents Of The University Of California |
Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
|
|
JPS6023084B2
(ja)
|
1979-07-11 |
1985-06-05 |
味の素株式会社 |
代用血液
|
|
US4376110A
(en)
|
1980-08-04 |
1983-03-08 |
Hybritech, Incorporated |
Immunometric assays using monoclonal antibodies
|
|
IE52535B1
(en)
|
1981-02-16 |
1987-12-09 |
Ici Plc |
Continuous release pharmaceutical compositions
|
|
US4640835A
(en)
|
1981-10-30 |
1987-02-03 |
Nippon Chemiphar Company, Ltd. |
Plasminogen activator derivatives
|
|
DE3374837D1
(en)
|
1982-02-17 |
1988-01-21 |
Ciba Geigy Ag |
Lipids in the aqueous phase
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
HUT35524A
(en)
|
1983-08-02 |
1985-07-29 |
Hoechst Ag |
Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
|
|
EP0143949B1
(en)
|
1983-11-01 |
1988-10-12 |
TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION |
Pharmaceutical composition containing urokinase
|
|
US4496689A
(en)
|
1983-12-27 |
1985-01-29 |
Miles Laboratories, Inc. |
Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
|
|
EP0154316B1
(en)
|
1984-03-06 |
1989-09-13 |
Takeda Chemical Industries, Ltd. |
Chemically modified lymphokine and production thereof
|
|
US4945050A
(en)
|
1984-11-13 |
1990-07-31 |
Cornell Research Foundation, Inc. |
Method for transporting substances into living cells and tissues and apparatus therefor
|
|
EP0206448B1
(en)
|
1985-06-19 |
1990-11-14 |
Ajinomoto Co., Inc. |
Hemoglobin combined with a poly(alkylene oxide)
|
|
CA1310924C
(en)
|
1986-04-24 |
1992-12-01 |
Francis P. Mccormick |
Infective drug delivery system
|
|
US4791192A
(en)
|
1986-06-26 |
1988-12-13 |
Takeda Chemical Industries, Ltd. |
Chemically modified protein with polyethyleneglycol
|
|
US4970154A
(en)
|
1987-10-09 |
1990-11-13 |
Baylor College Of Medicine |
Method for inserting foreign genes into cells using pulsed radiofrequency
|
|
EP0315456B1
(en)
|
1987-11-05 |
1994-06-01 |
Hybritech Incorporated |
Polysaccharide-modified immunoglobulins having reduced immunogenic potential or improved pharmacokinetics
|
|
US4892538A
(en)
|
1987-11-17 |
1990-01-09 |
Brown University Research Foundation |
In vivo delivery of neurotransmitters by implanted, encapsulated cells
|
|
US5106627A
(en)
|
1987-11-17 |
1992-04-21 |
Brown University Research Foundation |
Neurological therapy devices
|
|
US5158881A
(en)
|
1987-11-17 |
1992-10-27 |
Brown University Research Foundation |
Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
|
|
US5011472A
(en)
|
1988-09-06 |
1991-04-30 |
Brown University Research Foundation |
Implantable delivery system for biological factors
|
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
|
EP0401384B1
(en)
|
1988-12-22 |
1996-03-13 |
Kirin-Amgen, Inc. |
Chemically modified granulocyte colony stimulating factor
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5288855A
(en)
|
1989-01-23 |
1994-02-22 |
Farmitalia Carlo Erba |
Extracellular form of the human fibroblast growth factor receptor
|
|
DE69033109T2
(de)
|
1989-07-06 |
1999-11-18 |
The Regents Of The University Of California, Oakland |
Rezeptoren für fibroblasten-wachstumsfaktoren
|
|
US5676954A
(en)
|
1989-11-03 |
1997-10-14 |
Vanderbilt University |
Method of in vivo delivery of functioning foreign genes
|
|
HK1000547A1
(en)
|
1989-12-22 |
1998-04-03 |
Merck Serono Sa |
Endogenous gene expression modification with regulatory element by way of homologous recombination
|
|
US5272071A
(en)
|
1989-12-22 |
1993-12-21 |
Applied Research Systems Ars Holding N.V. |
Method for the modification of the expression characteristics of an endogenous gene of a given cell line
|
|
WO1991010470A1
(en)
|
1990-01-08 |
1991-07-25 |
Brown University Research Foundation |
Devices and methods for enhanced delivery of active factors
|
|
DE69133566T2
(de)
|
1990-01-12 |
2007-12-06 |
Amgen Fremont Inc. |
Bildung von xenogenen Antikörpern
|
|
US5672510A
(en)
|
1990-01-19 |
1997-09-30 |
Genetic Therapy, Inc. |
Retroviral vectors
|
|
DE69133281T2
(de)
|
1990-07-06 |
2004-05-06 |
Gencell S.A. |
Rezeptoren der wachstumsfaktoren aus fibroblasten
|
|
KR100272077B1
(ko)
|
1990-08-29 |
2000-11-15 |
젠팜인터내셔날,인코포레이티드 |
이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
|
|
US5217889A
(en)
|
1990-10-19 |
1993-06-08 |
Roninson Igor B |
Methods and applications for efficient genetic suppressor elements
|
|
US5252714A
(en)
|
1990-11-28 |
1993-10-12 |
The University Of Alabama In Huntsville |
Preparation and use of polyethylene glycol propionaldehyde
|
|
US5229501A
(en)
|
1991-01-11 |
1993-07-20 |
Chiron Corporation |
Expression and use of human fibroblast growth factor receptor
|
|
US6565841B1
(en)
|
1991-03-15 |
2003-05-20 |
Amgen, Inc. |
Pulmonary administration of granulocyte colony stimulating factor
|
|
IL100219A0
(en)
|
1991-12-02 |
1992-09-06 |
Yeda Res & Dev |
Variable region within fibroblast growth factor receptors that confers ligand specificity
|
|
US5470582A
(en)
|
1992-02-07 |
1995-11-28 |
Syntex (U.S.A.) Inc. |
Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
|
|
US5234784A
(en)
|
1992-04-01 |
1993-08-10 |
Eastman Kodak Company |
Method of making a projection viewable transparency comprising an electrostatographic toner image
|
|
US5364791A
(en)
|
1992-05-14 |
1994-11-15 |
Elisabetta Vegeto |
Progesterone receptor having C. terminal hormone binding domain truncations
|
|
ATE141958T1
(de)
|
1992-06-18 |
1996-09-15 |
Whittier Inst Diabetes & Endoc |
Verfahren zur detektion neoplastischer erkrankungen
|
|
WO1994002602A1
(en)
|
1992-07-24 |
1994-02-03 |
Cell Genesys, Inc. |
Generation of xenogeneic antibodies
|
|
US5474914A
(en)
|
1992-07-29 |
1995-12-12 |
Chiron Corporation |
Method of producing secreted CMV glycoprotein H
|
|
US5489743A
(en)
|
1993-01-19 |
1996-02-06 |
Amgen Inc. |
Transgenic animal models for thrombocytopenia
|
|
US5581476A
(en)
|
1993-01-28 |
1996-12-03 |
Amgen Inc. |
Computer-based methods and articles of manufacture for preparing G-CSF analogs
|
|
WO1994026122A1
(en)
|
1993-05-07 |
1994-11-24 |
Sterling Winthrop Inc. |
Lactose-hydrolyzed milk and milk products with improved taste and suppressed sweetness
|
|
US6664107B1
(en)
|
1993-05-26 |
2003-12-16 |
Ontario Cancer Institute, University Health Network |
CD45 disrupted nucleic acid
|
|
WO1994029442A2
(en)
|
1993-06-14 |
1994-12-22 |
Basf Aktiengesellschaft |
Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
|
|
US5589362A
(en)
|
1993-06-14 |
1996-12-31 |
Basf Aktiengesellschaft |
Tetracycline regulated transcriptional modulators with altered DNA binding specificities
|
|
US5654168A
(en)
|
1994-07-01 |
1997-08-05 |
Basf Aktiengesellschaft |
Tetracycline-inducible transcriptional activator and tetracycline-regulated transcription units
|
|
US5484720A
(en)
|
1994-09-08 |
1996-01-16 |
Genentech, Inc. |
Methods for calcium phosphate transfection
|
|
US5824784A
(en)
|
1994-10-12 |
1998-10-20 |
Amgen Inc. |
N-terminally chemically modified protein compositions and methods
|
|
US6096871A
(en)
|
1995-04-14 |
2000-08-01 |
Genentech, Inc. |
Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
|
|
JP4312259B2
(ja)
|
1995-04-27 |
2009-08-12 |
アムジェン フレモント インク． |
免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体
|
|
EP0828829A1
(en)
|
1995-05-26 |
1998-03-18 |
Zeneca Limited |
A gene switch comprising an ecdysone receptor
|
|
CA2219080A1
(en)
|
1995-06-07 |
1996-12-27 |
Ariad Gene Therapeutics, Inc. |
Rapamycin-based regulation of biological events
|
|
EP0832269A1
(en)
|
1995-06-07 |
1998-04-01 |
Baylor College Of Medicine |
Nucleic acid transporters for delivery of nucleic acids into a cell
|
|
DE69739853D1
(de)
|
1996-02-28 |
2010-06-02 |
Ariad Pharma Inc |
Synthetische rapamycinderivate als multimerisierende wirkstoffe für chimere proteine mit von immunophilin abgeleiteten domänen
|
|
US5679559A
(en)
|
1996-07-03 |
1997-10-21 |
University Of Utah Research Foundation |
Cationic polymer and lipoprotein-containing system for gene delivery
|
|
US6214795B1
(en)
|
1996-11-12 |
2001-04-10 |
Praecis Pharmaceuticals, Inc. |
Peptide compounds useful for modulating FGF receptor activity
|
|
WO1998029544A1
(en)
|
1996-12-26 |
1998-07-09 |
Kyowa Hakko Kogyo Co., Ltd. |
Novel peptide, novel dna, and novel antibody
|
|
US6133426A
(en)
|
1997-02-21 |
2000-10-17 |
Genentech, Inc. |
Humanized anti-IL-8 monoclonal antibodies
|
|
US6150098A
(en)
|
1998-02-20 |
2000-11-21 |
Amgen Inc. |
Methods for identifying novel secreted mammalian polypeptides
|
|
ZA200007412B
(en)
|
1998-05-15 |
2002-03-12 |
Imclone Systems Inc |
Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
|
|
US6548634B1
(en)
|
1998-09-30 |
2003-04-15 |
Chiron Corporation |
Synthetic peptides having FGF receptor affinity
|
|
WO2000027885A1
(en)
|
1998-11-05 |
2000-05-18 |
Kyowa Hakko Kogyo Co., Ltd. |
Novel chimeric polypeptide
|
|
US6656728B1
(en)
|
1999-02-08 |
2003-12-02 |
Chiron Corporation |
Fibroblast growth factor receptor-immunoglobulin fusion
|
|
CA2367375A1
(en)
|
1999-03-15 |
2000-09-21 |
Chiron Corporation |
Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
|
|
CA2311201A1
(en)
|
1999-08-05 |
2001-02-05 |
Genset S.A. |
Ests and encoded human proteins
|
|
US7408047B1
(en)
|
1999-09-07 |
2008-08-05 |
Amgen Inc. |
Fibroblast growth factor-like polypeptides
|
|
US7459540B1
(en)
|
1999-09-07 |
2008-12-02 |
Amgen Inc. |
Fibroblast growth factor-like polypeptides
|
|
AU7368100A
(en)
|
1999-09-10 |
2001-04-10 |
Curagen Corporation |
Fibroblast growth factor polypeptide and nucleic acids encoding same
|
|
WO2001032678A1
(en)
|
1999-11-05 |
2001-05-10 |
Smithkline Beecham Corporation |
sbgFGF-19a
|
|
DE60043197D1
(enExample)
|
1999-11-18 |
2009-12-03 |
Univ Kyoto |
|
|
US6716626B1
(en)
|
1999-11-18 |
2004-04-06 |
Chiron Corporation |
Human FGF-21 nucleic acids
|
|
WO2001038357A2
(en)
|
1999-11-22 |
2001-05-31 |
Millennium Pharmaceuticals, Inc. |
Jaffa, a novel fibroblast growth factor family member and uses therefor
|
|
US7108984B2
(en)
|
2000-01-12 |
2006-09-19 |
Mount Sinai School Of Medicine |
Methods of identifying modulators of the FGF receptor
|
|
US20020081663A1
(en)
|
2000-01-05 |
2002-06-27 |
Conklin Darrell C. |
Novel FGF homolog ZFGF11
|
|
AU2631001A
(en)
|
2000-01-05 |
2001-07-16 |
Zymogenetics Inc. |
Novel fgf homolog zfgf11
|
|
US20020001825A1
(en)
|
2000-03-31 |
2002-01-03 |
Nobuyuki Itoh |
Fibroblast growth factor-like molecules and uses thereof
|
|
JP2002112772A
(ja)
|
2000-07-10 |
2002-04-16 |
Takeda Chem Ind Ltd |
新規ポリペプチドおよびそのｄｎａ
|
|
IL139380A0
(en)
|
2000-10-31 |
2001-11-25 |
Prochon Biotech Ltd |
Active variants of fibroblast growth factor
|
|
US20030157561A1
(en)
|
2001-11-19 |
2003-08-21 |
Kolkman Joost A. |
Combinatorial libraries of monomer domains
|
|
US20060223114A1
(en)
|
2001-04-26 |
2006-10-05 |
Avidia Research Institute |
Protein scaffolds and uses thereof
|
|
US20040018499A1
(en)
|
2001-06-06 |
2004-01-29 |
Lal Preeti G |
Extracellular messengers
|
|
IL159177A0
(en)
|
2001-06-20 |
2004-06-01 |
Prochon Biotech Ltd |
Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
|
|
IL159524A0
(en)
|
2001-07-11 |
2004-06-01 |
Maxygen Holdings Ltd |
G-csf conjugates
|
|
US20040259780A1
(en)
|
2001-07-30 |
2004-12-23 |
Glasebrook Andrew Lawrence |
Method for treating diabetes and obesity
|
|
US20050187150A1
(en)
|
2001-10-31 |
2005-08-25 |
New York University |
Structure-based design and synthesis of FGF inhibitors and FGF modulator compounds
|
|
JP2005519891A
(ja)
|
2002-01-15 |
2005-07-07 |
イーライ・リリー・アンド・カンパニー |
危篤状態の患者における罹病率および死亡率を低下させる方法
|
|
ES2363765T3
(es)
|
2002-01-31 |
2011-08-16 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Agonistas de fgfr.
|
|
EP1332761A1
(en)
|
2002-01-31 |
2003-08-06 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Agonists of fibroblast growth factor receptors (FGFR)
|
|
IL149562A0
(en)
|
2002-05-09 |
2002-11-10 |
Prochon Ltd |
Fgf variants and methods for use thereof
|
|
JP2003334088A
(ja)
|
2002-05-22 |
2003-11-25 |
Pharma Design Inc |
ヒト由来の新規Ｋｌｏｔｈｏ様タンパク質及びその遺伝子
|
|
AU2003265057A1
(en)
|
2002-09-04 |
2004-03-29 |
Abtech |
Anti-idiotypic antibodies as vegf or fgf agonists for bone therapy
|
|
WO2004041170A2
(en)
|
2002-11-01 |
2004-05-21 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
|
WO2004056865A2
(en)
|
2002-12-20 |
2004-07-08 |
Enkam Pharmaceuticals A/S |
Method of modulation of interaction between receptor and ligand
|
|
WO2004083381A2
(en)
|
2003-03-13 |
2004-09-30 |
Indiana University Advanced Research & Technology Institute |
Fibroblast growth factor receptor-1 polynucleotides, polypeptides, and mutants
|
|
JP2006240990A
(ja)
|
2003-05-15 |
2006-09-14 |
Kirin Brewery Co Ltd |
ｋｌｏｔｈｏタンパク質および抗ｋｌｏｔｈｏタンパク質抗体ならびにそれらの用途
|
|
CA2528591C
(en)
|
2003-06-12 |
2013-01-08 |
Eli Lilly And Company |
Glp-1 analog fusion proteins
|
|
ES2298785T3
(es)
|
2003-06-12 |
2008-05-16 |
Eli Lilly And Company |
Proteinas de fusion.
|
|
WO2005019258A2
(en)
|
2003-08-11 |
2005-03-03 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
|
CA2762955A1
(en)
|
2003-10-16 |
2005-04-28 |
Imclone Llc |
Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof
|
|
CA2549249A1
(en)
|
2003-12-10 |
2005-07-07 |
Eli Lilly And Company |
Muteins of fibroblast growth factor 21
|
|
CA2550245A1
(en)
|
2003-12-19 |
2005-07-21 |
Five Prime Therapeutics, Inc. |
Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention
|
|
US20090111742A1
(en)
|
2004-01-26 |
2009-04-30 |
Alexei Kharitonenkov |
Use of fgf-21 and thiazolidinedione for treating type 2 diabetes
|
|
JP2007531715A
(ja)
*
|
2004-03-17 |
2007-11-08 |
イーライ リリー アンド カンパニー |
グリコール結合ｆｇｆ−２１化合物
|
|
JP4505631B2
(ja)
|
2004-03-31 |
2010-07-21 |
独立行政法人産業技術総合研究所 |
ヘパラン硫酸糖鎖を付加したヘパリン結合性タンパク質、その製造方法及びそれを含有する医薬組成物
|
|
US7576190B2
(en)
|
2004-05-13 |
2009-08-18 |
Eli Lilly And Company |
FGF-21 fusion proteins
|
|
US7622445B2
(en)
|
2004-09-02 |
2009-11-24 |
Eli Lilly And Company |
Muteins of fibroblast growth factor 21
|
|
ATE444307T1
(de)
|
2004-09-02 |
2009-10-15 |
Lilly Co Eli |
Muteine des fibroblasten-wachstumsfaktors 21
|
|
HUE026826T2
(en)
*
|
2004-10-29 |
2016-07-28 |
Ratiopharm Gmbh |
Modeling and glycopegylation of fibroblast growth factor (FGF)
|
|
JP2008522617A
(ja)
*
|
2004-12-14 |
2008-07-03 |
イーライ リリー アンド カンパニー |
線維芽細胞成長因子２１の突然変異タンパク質
|
|
EP1846019A2
(en)
|
2005-01-21 |
2007-10-24 |
Eli Lilly And Company |
Method for treating cardiovascular disease
|
|
JP2006246823A
(ja)
|
2005-03-11 |
2006-09-21 |
Kyoto Univ |
造血因子としてのＦｇｆ２１の使用
|
|
WO2006130527A2
(en)
|
2005-05-31 |
2006-12-07 |
Novartis Ag |
Mutations and polymorphisms of fibroblast growth factor receptor 1
|
|
EP2083081A1
(en)
|
2005-07-22 |
2009-07-29 |
Five Prime Therapeutics, Inc. |
Compositions and methods of treating disease with FGFR fusion proteins
|
|
ZA200800970B
(en)
|
2005-08-15 |
2009-10-28 |
Genentech Inc |
Gene disruptions, compositions and methods relating thereto
|
|
WO2007055789A2
(en)
|
2005-10-31 |
2007-05-18 |
Neose Technologies, Inc. |
Expression of soluble therapeutic proteins
|
|
KR20080108487A
(ko)
|
2006-02-28 |
2008-12-15 |
트르스티스 오브 보스톤 유니버시티 |
대사 조절인자 및 그의 용도
|
|
CA2655504A1
(en)
|
2006-06-15 |
2007-12-21 |
Fibron Ltd. |
Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
|
|
US20080248959A1
(en)
|
2006-07-21 |
2008-10-09 |
Neose Technologies, Inc. |
Glycosylation of peptides via o-linked glycosylation sequences
|
|
JP2010505874A
(ja)
|
2006-10-03 |
2010-02-25 |
ノヴォ ノルディスク アー／エス |
ポリペプチドコンジュゲートの精製方法
|
|
SG177225A1
(en)
|
2006-12-01 |
2012-01-30 |
Agency Science Tech & Res |
Cancer-related protein kinases
|
|
JP2010523084A
(ja)
*
|
2007-03-30 |
2010-07-15 |
アンブルックス，インコーポレイテッド |
修飾ｆｇｆ−２１ポリペプチド
|
|
LT2550972T
(lt)
|
2007-04-02 |
2018-05-10 |
Genentech, Inc. |
Kloto-beta agonistinis antikūnas, skirtas cukrinio diabeto arba atsparumo insulinui gydymui
|
|
JP5187837B2
(ja)
|
2007-04-06 |
2013-04-24 |
独立行政法人産業技術総合研究所 |
補助因子による受容体の活性化方法並びにリガンド活性の利用方法
|
|
US7537903B2
(en)
|
2007-04-23 |
2009-05-26 |
Board Of Regents, The University Of Texas System |
FGF21 upregulates expression of GLUT-1 in a βklotho-dependent manner
|
|
WO2008135993A1
(en)
|
2007-05-08 |
2008-11-13 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Klotho protein and related compounds for the treatment and diagnosis of cancer
|
|
EA200901550A1
(ru)
|
2007-05-22 |
2010-10-29 |
Новартис Аг |
Способы лечения, диагностирования и выявления ассоциированных с fgf21 нарушений
|
|
CA2689242C
(en)
|
2007-05-29 |
2015-07-07 |
Kohzoh Imai |
Agent and method for treatment of cancer
|
|
JP2010531135A
(ja)
|
2007-06-04 |
2010-09-24 |
ノボ ノルディスク アクティーゼルスカブ |
Ｎ−アセチルグルコサミニルトランスフェラーゼを使用したｏ結合型グリコシル化
|
|
EP2185178B1
(en)
|
2007-08-03 |
2017-08-23 |
Eli Lilly And Company |
Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity
|
|
US8426396B2
(en)
|
2008-01-08 |
2013-04-23 |
Shriners Hospitals For Children |
Treatment for achondroplasia
|
|
TW200936156A
(en)
|
2008-01-28 |
2009-09-01 |
Novartis Ag |
Methods and compositions using Klotho-FGF fusion polypeptides
|
|
US20110015345A1
(en)
|
2008-03-19 |
2011-01-20 |
Ambrx, Inc. |
Modified FGF-23 Polypeptides and Their Uses
|
|
JOP20190083A1
(ar)
|
2008-06-04 |
2017-06-16 |
Amgen Inc |
بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
|
|
WO2010006214A1
(en)
|
2008-07-09 |
2010-01-14 |
Ambrx, Inc. |
Fgf-21 neutralizing antibodies and their uses
|
|
RU2509774C2
(ru)
|
2008-08-04 |
2014-03-20 |
Файв Прайм Терапьютикс, Инк. |
Мутеины кислотной зоны внеклеточного домена рецептора фактора роста фибробластов
|
|
EP2358749B1
(en)
*
|
2008-10-10 |
2018-07-18 |
Amgen, Inc |
Fgf21 mutants and uses thereof
|
|
AU2010246038A1
(en)
|
2009-05-05 |
2011-12-01 |
Amgen Inc. |
FGF21 mutants and uses thereof
|
|
BRPI1011404B1
(pt)
|
2009-05-05 |
2022-05-03 |
Amgen Inc |
Polipeptídeos mutantes fgf21, polipeptídeo de fusão, multímero, composição farmacêutica, ácido nucleico isolado, vetor e célula hospedeira
|